The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy

Cancer immunotherapy and tumor microenvironment have been at the forefront of research over the past decades. Targeting immune checkpoints especially programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) has made a breakthrough in treating advanced malignancies. However, the low response rate...

Descripción completa

Detalles Bibliográficos
Autores principales: Long, Long, Zhang, Xue, Chen, Fuchun, Pan, Qi, Phiphatwatchara, Pronnaphat, Zeng, Yuyang, Chen, Honglei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305110/
https://www.ncbi.nlm.nih.gov/pubmed/30603054
http://dx.doi.org/10.18632/genesandcancer.180

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305110/
https://www.ncbi.nlm.nih.gov/pubmed/30603054
http://dx.doi.org/10.18632/genesandcancer.180

Ejemplares similares